deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT04407442

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

Phase II Study of Daratumumab in Combination With Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated With Daratumumab

Sponsor: Janssen Pharmaceuticals

Conditions Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma
Interventions Azacitidine Daratumumab Dexamethasone
Updated 15 times since 2020 Last updated: Apr 3, 2024 Started: Nov 30, 2020 Primary completion: Apr 30, 2023 Completion: Apr 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow enrollment and change in sponsor direction

Other terminated trials from Janssen Pharmaceuticals

See all terminations from Janssen Pharmaceuticals

Other Recurrent Plasma Cell Myeloma trials with similar outcome

Browse all Recurrent Plasma Cell Myeloma trials

A PHASE2 clinical study on Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma, this trial is terminated or withdrawn. The trial is conducted by Janssen Pharmaceuticals and has accumulated 15 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Jun 2022 · 12 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Aug 2023 · 6 months · monthly snapshot~Aug 2023 – ~May 2024 · 9 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Aug 2023 — May 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  5. Feb 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 10 earlier versions

  1. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  2. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  3. Jun 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  4. Mar 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  6. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Nov 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE2

  8. Sep 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE2

  9. Jul 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE2

  10. Jun 2020 — Jul 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Pharmaceuticals
  • Multiple Myeloma Research Foundation
  • University of California, San Francisco
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations